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The manufacture of medicines is subject to licence. To
ensure that the manufacture of the medicinal products is
appropriate is one part of the evaluation of marketing
authorisation applications. It is the responsibility of the
competent authorities in EU member states to ensure
that the pharmaceutical industry complies with the mu-
tually agreed Good Manufacturing Practices (GMP),
and that the medicinal products on the market are also
in practice manufactured in accordance with the mar-
keting authorisation. Implementation of GMP-require-
ments is  an integral part of safety of medicinal prod-
ucts, which is supervised by regular inspections of phar-
maceutical manufacturing plants. 
Even outside the EU, the manufacturers of medicinal
products intended for the EU market are required to
comply with the EU GMP-requirements. The inspecting
of these pharmaceutical plants relies on co-operation be-
tween member states. 
The structural changes in the pharmaceutical indus-
try during recent years pose new challenges to the su-
pervisory authorities. These days, the manufacturing
processes of medicines have been divided into part
processes, many of which are delegated to subcontrac-
tors. It is now increasingly common that several manu-
facturers are jointly responsible for the various process-
es in the production of medicines; one plant is responsi-
ble for the production of the active pharmaceutical in-
gredient, another one processes e.g. the tablets, a third
one packs the medicine, a fourth one performs the qual-
ity control testing, while the fifth one releases the medi-
cine on the market. Furthermore, the production of
medicines is increasingly being transferred to countries
with cheap labour. Although the holder of the market-
ing authorisation is situated in the EU, the medicine
may actually be produced outside the EU. Authorities
need to be aware of the problems arising from the
above mentioned practices. 
Professionals of marketing authorisation documenta-
tion and filing within the EU are capable to fulfill au-
thorities’ formal requirements concerning the content of
documents and files. Responsible persons participating
in the production of medicines in pharmaceutical plants
on the other side of the world do not necessarily know
how the manufacturing process has been described in
the marketing authorisation, or what are the GMP-re-
quirements in the EU for the manufacture of the medi-
cine in question. It has actually happened that an in-
spector has been taken to a totally different plant than
to the one stated in the marketing authorisation. A fur-
ther cause for concern are cases, where the applicant for
marketing authorisation after announcement of coming
inspection immediately reports to transfer the produc-
tion to another plant. To ensure the safety of pharma-
ceuticals is, with reason, more than just an assessment
of the written documentation.
As part of the inspection team of the EU supervisory
authorities, the inspectors of the Finnish National
Agency for Medicines (NAM) perform inspections on
behalf of the whole EU. Once a foreign pharmaceutical
plant is included in NAM’s inspection program, the
NAM remains in charge of the evaluation of the manu-
facturer’s GMP-compliance for as long as the relevant
marketing authorisation is in force. NAM’s inspection
program covers, in addition to domestic ones, pharma-
ceutical plants around the world, for instance in the
USA, India and Japan. 
In future the inspection activities are expanding even
more. In addition to the regulations concerning autho-
rised medicinal products, there are already statutory
GMP requirements applicable at Community level for
investigational medicinal products used in clinical trials.
In connection with the review of Community legislation,
similar requirements will also be applicable to the man-
ufacturer of active pharmaceutical ingredients. Once the
new legislation comes into force, NAM’s inspectors will
inspect, in addition to the domestic active pharmaceuti-
cal ingredients manufacturers, also pharmaceutical
plants situated outside the EU, in accordance with the
EU’s standards. The increasing and active co-operation
of inspectors  in EU will, with the harmonisation of
GMP requirements and interpretations, also cover these
sub-sectors of pharmaceutical industry.
Eija Pelkonen
HEAD OF INSPECTORATE
National Agency for Medicines
Inspections by National Agency for Medicines –
part of the EU’s medicine control
Editorial
Summary 
Translation Sari Jay
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With drug consumption rising in all
age groups the proportion of the el-
derly population in the consump-
tion-related figures is rapidly grow-
ing (1). As the consumption mounts
the concomitant use of several drugs
is becoming more common all the
time, and as high a proportion as
15% of the elderly on multi-drug
therapy suffer from undesirable drug
interactions (2).
The most important risk of and
condition for developing interactions
is the concomitant use of two or
more drugs. In addition to drugs,
patients (and healthy individuals) al-
so use various herbal medicinal
products, alternative ‘natural prod-
ucts’, functional food, and other
products containing pharmacologi-
cally active ingredients. It is recom-
mended that the physician asks
his/her patient about the use of all
the above-mentioned products. The
attending clinician should be in-
formed about any special diet the
patient may be on. 
Considering the extensive use of
multi-drug therapies, the number of
serious drug interactions is relatively
low (3). By identifying the risk fac-
tors leading to interactions, the situ-
ation may be brought under control.
The risks of interactions between
medicinal substances can be divided
into two groups: factors induced by
drugs and factors induced by the pa-
tient. Drug interactions appear
mostly when two or more risk-car-
rying drugs are administered to the
patient at risk.
What is a risk-carrying drug?
Interactions are classified as phar-
macokinetic and pharmacodynamic
interactions according to the mecha-
nisms by which they are generated.
A pharmacokinetic adverse reaction
develops because the plasma drug
concentrations are changed. A phar-
macodynamic interaction develops
in the target structure (receptor) of
the drug without changes in the
plasma drug concentrations. For the
understanding of interactions it is
important to distinguish the drug ei-
ther as “an inducer drug” or “a tar-
get drug”. A target drug is a drug
which causes an undesirable effect
following a change in its concentra-
tion in the plasma (in the body). The
inducer drug is, as its name suggests,
the element which changes the kinet-
ics or dynamics of the target drug in
such a way that an undesirable ef-
fect is produced (3).
Since the target drug is the in-
ducer of the final undesirable effect,
its characteristics are the crucial in-
dicators of the seriousness of the ad-
verse reaction (4). There are large
variations between different drugs in
this respect. Even a small change in
a plasma warfarin concentration
may cause haemorrhages (increased
concentration) or prevent a response
to treatment (decreased concentra-
tion). However, drugs with a wide
therapeutic spectrum, e.g. antimicro-
bials of the penicillin group, do not
produce undesirable effects despite
even large changes in their concen-
trations in plasma.
It should be borne in mind that
the inducer drugs can be found in
any therapeutic group with greatly
varying characteristics. Well tolerat-
ed drugs such as itraconazole and
erythromycin may be important in-
ducers of interactions. The key risk-
inducing characteristics of a target
drug are presented in Table 1.
The first three characteristics
mentioned are those most important
in practice because the dangerous ef-
fect, steep dose response and dose
dependent toxicity can cause an ad-
verse reaction in the patient leading
at the worst to death. On the other
hand, prevention of response, e.g.
reduced analgetic effect of codeine
as a result of prevention of the
CYP2D6 enzyme, seldom poses a
danger to the patient in practice.
Drugs which increase the medicinal
substance metabolism inhibit in par-
ticular the effect of oral contracep-
tives, the possible result being preg-
nancy despite regular use of the con-
traceptive pill (5). Phenytoin is an
example of a medicinal substance,
the metabolism of which, and conse-
quently the elimination of which
from the body, become saturated
even at therapeutic doses. Fortunate-
ly, this happens with only a few
medicinal substances.
How does the risk of drug interactions develop?
Hannu Raunio
PROFESSOR
Department of Pharmacology and Toxicology
University of Kuopio
Summary 
Table 1 .  Risk- inducing character-
ist ics  of  medicinal  substances
Risk-inducing Example of
characteristic a drug
Dangerous Warfarin
effect
Steep dose Verapamil
response
Dose dependent Digoxin
toxicity
Prevention Codeine
of response
Prevention Oral contra-
of prophylaxis ceptives
Metabolism which Phenytoin
becomes saturated 
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What puts a patient at risk?
Several factors, dependent on the
patient, influence the risk of occur-
rence of drug interactions. The most
important factors include the pa-
tient’s age, diseases and the structure
of the genes affecting the drug re-
sponse (Table 2). Several different
clinicians attending to the patient at
the same time is also a risk factor.
Age
The special features of drug treat-
ment in children amount to due con-
sideration being given in the phar-
maceutical kinetics and dynamics to
the child’s growth and development
(6). Compared with adults and older
children, the newborn have an inad-
equate ability to eliminate many of
the medicinal substances. Should the
drug administered be toxic, this
could lead to serious adverse reac-
tions. Lethal grey baby syndrome in
neonates caused by chloramphenicol
serves as a classical example.
The elderly are a distinct risk
group. They use a lot of drugs, they
have several diseases, and they go
through physiological changes which
promote the development of interac-
tions. The elimination of medicinal
substances is reduced in the elderly
whose responses at the receptor level
may also have altered (7). A good
practical example is an accentuated
response to anticholinergic drugs –
concomitant use of many antipsy-
chotics, drugs used in Parkinson’s
disease and analgesics may result in
an unexpected accumulation of ef-
fects and cause undesirable effects
such as constipation, urinary reten-
tion and confusion (8).
Organ insufficiency and additional
diseases
Many diseases, in particular those
which result in hepatic and renal im-
pairment, change the kinetics and
dynamics of medicinal substances.
Acute and chronic liver diseases may
affect the plasma binding of drugs,
hepatic blood circulation, drug me-
tabolism, distribution in the body
and also the body’s sensitivity to
drug effects (9). In renal failure, the
urinary excretion of medicinal sub-
stances is prevented, and there may
also be changes in the metabolism,
distribution and the sites of activity
of the substances (10). Heart failure
also affects the kinetics of several
drugs.
The liver’s capacity for the me-
tabolism of foreign substances is
very high, and consequently in prac-
tice only very advanced liver disease
will significantly change the effects
of drugs on the body. Renal impair-
ment is, however, a physiological
phenomenon; the hepatic function
of an 80-year-old is only about a
half that of a 30-year-old. Many
drugs, the anti-inflammatory anal-
gesics in particular, often impair the
renal function even further in the el-
derly. A distinct difference in prac-
tice between hepatic and renal im-
pairment is also the fact that the re-
nal function is easy to measure
whereas the hepatic function may be
impaired in various ways by several
different diseases and the function is
difficult to assess (9, 10).
In addition to the disease being
treated, drug therapy should also
cover other diseases and conditions
which may greatly influence the
practicalities of the therapy (11).
Some examples of general additional
diseases are presented in Table 3;
they may cause or exacerbate the
undesirable effects caused by drug
interactions.
Abnormal gene structure
The final drug response is influenced
by several proteins (enzymes, trans-
port proteins, receptors); where
there is great variation in the genes
which code for them in the popula-
tion (genetic polymorphism). 
Several deviant forms (alleles) of
these genes which may result in un-
expected responses to drugs are, of
course, known at present (12). One
of the best known examples is prob-
ably the liver enzyme CYP2D6, of
which an inactive variant occurs in
about 7% of the Finnish population.
In these individuals, drugs metabol-
ised mainly via the CYP2D6 enzyme
are eliminated at a slower rate than
normal, which may even result in se-
rious adverse reactions.
It is clearly evident that abnor-
mal gene structures may even cause
very serious adverse reactions during
drug therapy. The following chain of
events is suspected of having caused
fatal interactions. The patient is us-
ing drug X, which  prolongs the QT
interval. The elimination of this
drug  is dependent on the activity of
the CYP2D6 and CYP3A4 enzymes.
The patient has a genetic deficiency
of the CYP2D6 enzyme, and this
route of metabolism is not function-
ing. Up till now all is well, however,
as CYP3A4 takes care of the drug
metabolism and therefore also the
elimination. The patient is then giv-
Table 3.  The effect  of  addit ional  disease on the drug therapy
Disease Drug which exacerbates the disease
Digestive tract 
- mucosal damage Anti-inflammatory analgesics, glucocorticoids
- constipation Opioids, anticholinergics
Neurological and mental diseases
- epilepsy (convulsions) Antipsychotics, tricyclic antidepressants, 
amantadine, caffeine, fluoroquinolones
- dementia Anticholinergics (tricyclic antidepressants, 
several neuroleptics)
Other diseases
- asthma Beta-blockers
- diabetes Diuretics, beta-blockers, glucocorticoids
Table 2.  Risk- inducing character-
ist ics  of  pat ients
Risk-inducing Examples
characteristic
Age Newborn, an elderly 
patient
Organ function Impaired hepatic and 
impairment renal function
Additional Gastric ulcer
diseases asthma, 
dementia
Abnormal gene Non-functioning
structure CYP2D6 enzyme 
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en additional medication, itracona-
zole, for example, which blocks the
CYP3A4-mediated metabolism. This
causes the drug X concentration in
plasma to rise dangerously high and
the patient suffers torsades de
pointes. If the same patient also
happens to have a genetic mutation
affecting the cardiac potassium
channel causing liability to prolon-
gation of the QT interval, the condi-
tions are in place for a lethal adverse
reaction. This is suspected to have
been the case with the use of terfe-
nadine, even though complete cer-
tainty cannot be reached with any
medicinal substance.
Which drugs should be 
monitored?
Numerous sources of information
on drug interactions are available in-
cluding fairly complete lists of inter-
acting medicinal substances. Table 4
is a short list of some of the sub-
stances which in recent years have
been in the forefront as targets and
inducers of pharmacokinetic interac-
tions. The table lists some of the
most important examples.
Several important interactions
which develop on the basis of phar-
macodynamics are known in addi-
tion to those listed above. Drug
combinations with mechanisms to
increase the amount of serotonin at
the nerve ends have been in the fore-
front recently. A popular analgesic,
tramadol, increases the amount of
serotonin and when used concomi-
tantly with antidepressants it may
cause an excessive serotonin effect
(13).
Conclusion
It is possible to reduce the risks of
drug interactions by understanding
the risk factors associated with the
drug and the patient. The role of ge-
netic factors in the drug adverse re-
actions and interactions is rapidly
becoming clear, and in the future,
with the help of genetic tests, we
may possibly be able to avoid the
use of dangerous drug combinations
in sensitive patient groups. The gen-
eral rule of drug therapy is: avoid
using two or more risk-inducing
drugs concomitantly in a patient at
risk!
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Table 4.  Examples of  medicinal  substances which in pract ice have a marked possibi l i ty  of  causing pharmaco-
kinet ics  interact ions
Target drug Concentration is increased Concentration is decreased 
by (inducer drug) by (inducer drug)
Warfarin, tolbutamide Miconazole, gemfibrozil Hypericum perforatum
Lovastatin, felodipine, midazolam, Itraconazole, erythromycin, Carbamazepine, phenytoin,
cisapride, ciclosporin, buspirone chlarithromycin, grapefruit juice Hypericum perforatum
Digoxin Quinidine, verapramil Rifampicin
Imipramine, amitriptylin, metoprolol Fluoxetin, quinidine
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Last year, the ADR register of the
National Agency for Medicines
received a total of 936 reports of
suspected adverse drug reactions,
almost half of which were serious.
At least ten reports were received on
twenty-one drugs.
Several of the medicinal sub-
stances at the top of the list have
been recently introduced on to the
market and are therefore usually
more frequently the subject of
reports than old well-known drugs.
The list cannot be used for compari-
son of safety between the medicinal
substances as such because of the
great variation in the exposure:
more reports may be received on a
drug which is frequently used than
on a drug which is used more infre-
quently despite the possibility of
equal incidence of adverse reactions.
Antimicrobials
The largest number of ADR reports
concerned an antibacterial agent of
the fluoroquinolone group, lev-
ofloxacin (30 reports). The majority
of them (23) were of adverse reac-
tion in the Achilles tendon (ten-
donitis or tendon rupture). By the
end of 2003, altogether 97 cases of
adverse reactions in the tendon were
reported, 66 of which had occurred
in association with levofloxacin
therapy. The majority of the cases
involved elderly patients (67±13
years), and 76% were male. Con-
comitant medication with corticos-
teroids increases the risk of tendon
rupture. If the patient is suspected of
having tendonitis, the use of fluoro-
quinolones should be stopped imme-
diately.
Telithromycin is a new antibiotic
of the ketolide group and structural-
ly closely related to the macrolide
antibiotics. The drug was introduced
on to the Finnish market in mid-
2002. Last year a total of 20 ADR
reports were made on it, six of
which involved a skin reaction; five
involved nausea and five visual dis-
turbances. Nausea is listed as a com-
mon undesirable effect in the SPC
(1–10% of the patients), whereas
adverse effects on the skin and visu-
al disturbances are uncommon
(0.1–1%). The SPC of telithromycin
was updated in 2003 and physicians
were warned about the use of the
drug in myasthenia gravis patients,
because telithromycin may exacer-
bate the symptoms of the disease.
Nitrofurantoin, used for urinary
tract infections, was the subject of a
report on 13 occasions. On ten of
the occasions the cause of the ADR
report was a pulmonary reaction
(alveolitis, pulmonary infiltrate or
pulmonary fibrosis); one patient was
also reported as having dyspnoea.
Due to the risk of serious pul-
monary reactions, all respiratory
symptoms such as cough or dysp-
Reports received by the adverse drug reaction
register in 2003
Marja-Leena Nurminen
SENIOR MEDICAL OFFICER
Leena Sommarberg
RESEARCHER
Safety&Drug Information
National Agency for Medicines
Summary 
ADR News
The medicinal  substances most  f requently  reported to the ADR register
of  the National  Agency for  Medicines during 2003
Medicinal substance Number of reports
levofloxacin (Tavanic) 30
jopromide (Ultravist) 27
celecoxib (Celebra) 26
clozapine (several products, e.g. Leponex, Froidir) 26
rofecoxib (Vioxx, Vioxxakut) 25
simvastatin (several products, e.g. Corolin, Lipcut, Zocor) 21
telithromycin (Ketek) 20
ethoricoxib (Arcoxia) 20
infliximab (Remicade) 19
terbinafine (Lamisil) 17
atorvastatin (Lipitor) 15
quetiapine (Seroquel) 14
risperidone (Risperdal) 14
ethinylestradiol + ethonogestrel (Nuvaring vaginal ring) 14
ethinylestradiol + drospirenone (Yasmin) 13
fluvastatin (Canef, Lescol) 13
nitrofurantoin (Nitrofur-C) 13
venlafaxine (Efexor) 12
carbamazepine (several products, e.g. Tegretol, Neurotol) 11
bupropion (Zyban) 11
mirtazapine (Remeron) 10
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noea, occurring in patients on nitro-
furantoin therapy, should receive
special attention.
As in previous years, the majori-
ty of adverse reactions reported con-
cerning antimycotics involved
terbinafine tablets (17 reports). The
most common reactions included
taste disturbances (9) and various
skin reactions (5).
Antiinflammatory and 
antirheumatic agents
Last year, altogether 78 adverse
reactions were reported as having
been associated with the use of the
COX 2-selective anti-inflammatory
analgesics, etoricoxib, rofecoxib,
celecoxib and valdecoxib, six of
which involved serious haemorrhage
or ulcer in the gastrointestinal tract
(celecoxib 3, etoricoxib 2, rofecoxib
1). Nearly all the patients involved
were elderly, over 70 years of age.
The majority of the adverse reac-
tions associated with celecoxib were
various allergic reactions and rashes
(11). Symptoms indicative of allergic
reactions were also reported during
the use of etoricoxib (7). The use of
rofecoxib was associated with e.g.
oedema, weight increase and/or
serum creatinine elevation (7). Two
patients on rofecoxib therapy were
reported as having suffered from
lithium intoxication with the con-
comitant use of rofecoxib and lithi-
um. The SPC includes a warning
about increased plasma lithium con-
centrations due to non-steroidal
anti-inflammatory analgesics, and
also about the increased plasma
lithium levels reported in the use of
rofecoxib.
As in previous years, the most
frequently reported antirheumatic
drug was infliximab (19 reports),
which is used in severe, active
rheumatoid arthritisand in Crohn’s
disease when, for example, an ade-
quate response has not been achiev-
ed with other drugs. The drug was
granted marketing authorisation
through the centralised procedure of
the EU at the end of 1999. The most
commonly reported adverse reac-
tions associated with infliximab
therapy last year were serious hyper-
sensitivity reactions (6). Liver reac-
tion was reported in three patients
and tuberculosis in two. Reduced
defence against infections has been
reported in some patients who had
received infliximab. Since the mar-
ket introduction of the drug, infec-
tions have indeed been the most
common serious adverse reaction
worldwide. The SPC contains a
reminder of the necessity of assess-
ing both active and latent tuberculo-
sis in all patients before infliximab
therapy. By the end of 2003 the
National Agency for Medicines had
received a total of 54 reports of
adverse reactions associated with the
use of infliximab, seven of which
concerned tuberculosis; one of the
patients died. On three other occa-
sions, the patient died of a serious
infection.
Antipsychotics and 
antidepressants
The majority of reports on antipsy-
chotics concerned the so-called sec-
ond generation antipsychotics,
clozapine (26), risperidone (14) and
quetiapine (14). The majority of the
reports on clozapine concerned
granulocytopenia or agranulocytosis
(14). Due to haematological
changes, the leukocyte count should
be checked before the start of the
treatment and regularly during the
medication. Hyperglycaemia was
reported in two patients who had
been on clozapine therapy, and dia-
betes mellitus in one patient. All the
cases were serious and resulted in
hospitalisation. Medical associations
in the USA have recently reported
on the risk of weight increase and
diabetes associated with the use of
atypical neuroleptics (Diabetes Care
27: 596-601, 2004), which appears
to be connected in particular with
clozapine and olanzapine therapy.
The use of risperidone and quetiap-
ine is also associated with weight
increase, but there are discrepant
research results regarding the risk of
diabetes.
Two patients who had received
clozapine were reported as having
had a serious cerebrovascular acci-
dent. 
Adverse reactions reported con-
cerning the use of quetiapine last
year included cases of hyperprolacti-
naemia (2), malignant neuroleptic
syndrome (1), orthostatic hypoten-
sion (1) and extrapyramidal symp-
toms (1), which are all typical unde-
sirable effects associated with neu-
roleptic therapy. One patient on
quetiapine therapy was reported as
having prolongation of the QT
interval associated with  life threat-
ening torsades de pointes tachycar-
dia. Prolongation of the QT interval
is a potent adverse effect with all
neuroleptics, but the most evidence
of this effect exists onsertindole,
thioridazine, pimozide and haloperi-
dol. Pimozide is no longer available
on the Finnish market.
Serious neurological adverse
reactions caused by risperidone (dys-
tonia, extrapyramidal disorder, tar-
dive dyskinesia) were reported in
three patients and malignant neu-
roleptic syndrome in one patient.
The report on two patients was
made on account of a liver reaction
and on one patient because of a pro-
longation of the QT interval.
The majority of reports received
on antidepressants concerned ven-
lafaxin (12 reports) and mirtazapine
(10 reports). Two patients on ven-
lafaxin therapy were reported as
having prolongation of the QT
interval, and one of them was also
found to have torsades de pointes.
In addition, the reason for reporting
the incident in one patient was
unconsciousness, but the report did
not reveal further information on
any arrhythmia. Two patients on
venlafaxin therapy, one of whom
was also receiving mirtazapine, were
reported as having a serotonin syn-
drome.
Bupropion, also belonging to the
group of antidepressants, was the
object of an ADR report on 11
occasions. However, bupropion is
not used for the treatment of depres-
sion in Finland, but is indicated for
patients trying to quit smoking,
together with other motivating sup-
port measures. Nine of the reports
referred to an allergic reaction or a
skin reaction.
Hormones
The use of one of the new contra-
ceptive products, NuvaRing, which
contains etonogestrel and ethinyl-
estradiol, was reported as having
been associated with 13 unintended
pregnancies and one pulmonary
embolism.  There were 13 ADR
reports last year on combination
oral contraceptive containing
drospirenon and ethinylestradiol,
seven of which concerned a throm-
boembolic complication (pulmonary
embolism, cerebrovascular thrombo-
sis or myocardial infarction or
ischaemia). The use of hormonal
contraceptives, including the contra-
ceptive device, has been associated
with an increased risk of venous and
arterial thrombosis. The extent of
the risk of these more recent hor-
monal contraceptives compared
with that of the older combination
oral contraceptives is at present
unknown.
Serum lipid reducing agents
Cholesterol-synthesis-inhibiting
statins were the reason for a total of
60 reports of adverse reactions
received by the NAM in 2003. The
majority of them concerned simvas-
tatin (21 reports), atorvastatin (15)
and fluvastatin (13). The most
recently introduced statin, rosuvas-
tatin (Crestor), was also reported on
quite frequently last year (7), con-
sidering that the drug had not been
available on the market until July
2003. The most commonly reported
adverse reactions associated with
statins were myalgia and/or elevated
creatinine phosphokinase levels (19)
and liver reactions (elevated enzyme
levels or hepatitis; 17 reports).
Contrast media
Iopromide is an iodine-containing
contrast medium of low osmolality
which is used in angiography, urog-
raphy and contrast medium
enhanced computed tomography
imaging. The Agency received a
total of 27 ADR reports on this one
in 2003, the majority of which con-
cerned allergic reactions, as in previ-
ous years. Special care should be
exercised in the use of the product
in patients with hypersensitivity to
iodine containing contrast media.
Patients with allergic tendencies in
general are more inclined to suffer
from hypersensitivity reactions than
others. An attempt might be made
to prevent them by the administra-
tion of antihistamines and/or corti-
costeroids to the patient before the
examination.
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The level of consumption of antipsy-
chotics appears to have remained
more or less unchanged for the past
20 years in Finland (Fig.). Since the
beginning of the 1990's the increased
and stabilised use of clozapine has
been reflected in the sales statistics,
and, during the last five years, other
'atypical', i.e. second generation, an-
tipsychotics have increased their pro-
portion to over a third of all those
used. This is also manifested in the
adverse drug reactions register, where
there are plenty of reports on older
drugs dating back to the first years
of the register, but where the new
drugs start to appear in recent years.
This article aims to review the most
common adverse reactions caused by
antipsychotics and reported in the
ADR (adverse drug reactions) regis-
ter of the NAM, both during the en-
tire period of 30 years and the past
10 years, i.e. since 1994.
A total of 974 reports have been
received by the ADR register on ad-
verse reactions caused by antipsy-
chotics, more than half of which
were received during the past 10
years. The number of reports sent in
nowadays is consequently higher
than before. This probably reflects
the increase in the general reporting
activity, on the one hand, and, on the
other hand, the fact that new drugs
are reported on more often than old
ones, and, in this instance, that the
use of clozapine has increased and,
as a result, so have also the adverse
reactions caused by it. The figures
presented overlap, i.e. several drugs
may be under suspicion, and several
different harmful effects be men-
tioned, in one and the same report.
The complete data 
In half of the cases reported, the
suspected drug is clozapine (484 re-
ports). The reports disclose harmful
effects on the blood typical of cloza-
pine, such as leukocytopenia, granu-
locytopenia and agranulocytosis, of-
ten with associated signs of infec-
tion. The use of clozapine is sus-
pected of having caused 22 fatali-
ties, and in Finland the drug has in
fact been under restrictions with re-
gard to use and has been later rein-
troduced on to the market with new
safety instructions. Twelve of the fa-
talities associated with the use of
clozapine are suspected of having
been caused by infections due to
blood count changes; in five of the
cases, increased drug concentrations
have been detected.
The second highest number of
reports (75) on adverse drug reac-
tions was received regarding chlor-
promazine, which has been widely
used for a long time; typical harm-
ful effects include symptoms of dis-
ordered liver function, e.g. elevated
hepatic values, jaundice and hepati-
tis (22). A total of 17 reports have
been received of various blood
count changes, and 11 of malignant
neuroleptic syndrome. As a result of
reports on levomepromazine and
promazine, the total number of re-
ports in this group is increased to
slightly over 100, but they hardly
make any difference to the distribu-
tion of adverse reactions.
Risperidone with its 71 reports
appears to be the third largest cause
for reporting. It is suspected, for ex-
ample, of having caused hyperpro-
lactinaemia and/or menstrual distur-
bances (17 cases), malignant neu-
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roleptic syndrome (8 cases), delays
in the QT interval (5 cases) and
blood count changes (4 suspected
cases). Typical undesirable effects of
antipsychotics also include extra-
pyramidal symptoms, movement dis-
orders, tremor and increased saliva-
tion which have been reported on
12 occasions.
Olanzapine, having been a slight-
ly shorter time on the market and
with its 52 reports, ranks fourth on
the list of adverse reactions caused
by antipsychotics. Among the vari-
ety of symptoms reported, the ma-
jority have been of hyperprolacti-
naemia or milk secretion (6), blood
count changes (6), malignant neu-
roleptic syndrome (6) and various
types of oedema (5 reports).
Quetiapine is surpassed by
haloperidol, used widely for a long
time, with 43 reports, and thiori-
dazine with 39 reports. More than
half of the reports on haloperidol
(22) were of malignant neuroleptic
syndrome, three of tardive dyskine-
sia, three of extrapyramidal symp-
toms and three of various types of
arrhythmia, with the rest of the cas-
es figuring as isolated reports. In six
of the cases of malignant neuroleptic
syndrome, another antipsychotic
was also suspected. The use of thior-
idazine has revealed blood count
changes (8 reports), arrhythmia (6)
and malignant neuroleptic syndrome
(3 reports). Adverse reaction was
suspected of having caused six fatal-
ities.
Quetiapine is the most recent an-
tipsychotic in the market which be-
comes evident in the increased num-
ber of reports (38). The frequency of
reporting is usually reduced as clini-
cians become familiar with the drug
and new, 'more interesting' drugs
are introduced on to the market. Re-
porting may also be increased by
disappointment caused by the new
medicinal substances: the expecta-
tions are high, but there is no mira-
cle drug discovered. Eight cases of
agranulocytopenia, five cases of neu-
roleptic syndrome, three cases of ar-
rhythmia and a variety of other
symptoms have been linked with the
use of quetiapine.
The rest of the adverse reactions
are spread over several drugs, but
yet another prominent place in this
group is occupied by lithium with
32 reported cases, six of which refer
to a thyroid gland disorder and five
involving elevated drug concentra-
tions, three of which were suspected
of having been caused by a drug in-
teraction. The dreaded renal effects
were suspected in only two cases.
Adverse reactions caused by an-
tipsychotics in 1994–2003
In the past 10 years, 564 reports
have been made on the adverse reac-
tions caused by antipsychotics. A
high proportion of these, i.e. 306 re-
ports, again concerned clozapine
and especially the blood count
changes caused by it. As the more
recent antipsychotics have replaced
the use of the older ones, the majori-
ty of reports even in this group, af-
ter clozapine, concerned the so-
called "newer antipsychotics". The
majority of the reports were firstly
of risperidone (65 reports), followed
by olanzapine (45 reports) and
thirdly, quetiapine (36 reports).
Most of these adverse reactions have
been discussed above.
Even though the use of newer
drugs increased during that period,
there were still reports of several se-
rious adverse effects. Hence malig-
nant neuroleptic syndrome was re-
ported on a total of 45 occasions.
The majority of the reports con-
cerned clozapine (8 cases), followed
by risperidone (8 reports), then sev-
en cases concerning haloperidol, six
cases concerning quetiapine and
olanzapine, four cases concerning
zuclopenthixol, and in isolated cases
a few other preparations.
Forty-four reports were made on
adverse reactions associated with the
heart, as a rule concerning some
types of arrhythmia with or without
a delayed QT interval. 
Clozapine appears in these re-
ports 12 times, risperidone 8, both
sertindole and quetiapine 7 and
olanzapine five times. 
Sertindole is not discussed in de-
tail as it was on the market only for
a short time.
The data covering 10 years in-
cludes 32 cases of adverse effects on
the blood, mainly agranulocytosis or
granulocytopenia, without the in-
volvement of clozapine. The drugs
under suspicion include quetiapine
(8 cases), olanzapine (7 reports),
risperidone and levomepromazine (4
reports each), as well as some isolat-
ed reports on other drugs.
Reports were made of milk secre-
tion or hyperprolactinaemia on 29
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occasions, on 17 of which risperi-
done was the culprit suspected.
Olanzapine was mentioned six
times, and both sertindole and queti-
apine twice, but clozapine was not
mentioned once. In addition to
these, risperidone is mentioned in
two cases, the symptom being given
as amenorrhoea.
Liver reactions were reported 28
times with symptoms varying be-
tween elevated enzyme levels and se-
vere liver damage. Clozapine ap-
pears in this group, too, with 11 re-
ports; chlorpromazine and risperi-
done are the suspected causes in five
cases, olanzapine in four, quetiapine
in two cases and chlorprothixene
once. 
Oedema has been reported on 11
occasions. It is thought to have been
caused by olanzapine five times,
quetiapine four times, and once each
by both risperidone and chlorpro-
mazine.
Extrapyramidal symptoms have
been mentioned in the reports on 10
occasions, three of which were asso-
ciated with risperidone, two with
perphenazine and the rest with iso-
lated drugs including, for example,
quetiapine from among the more re-
cent drugs.
In the reports involving convul-
sions (8 cases) clozapine was sus-
pected on three occasions, olanzap-
ine and sertindole twice and risperi-
done once.
In the cases of tardive dyskinesia,
olanzapine, risperidone and sertin-
dole were each suspected as the
cause twice, and haloperidol once, a
total of seven occasions. Except for
one 80-year old female, the ages of
the patients ranged between 21 and
50 years.
A total of 27 deaths have also
been reported during the past 10
years. In 10 of the cases a report
was made concerning clozapine, but
even olanzapine and risperidone
were suspected, both on three occa-
sions, albeit risperidone was used in
combination. There were isolated re-
ports concerning chlorpromazine
(several concomitant drugs), levome-
promazine, haloperidol and pro-
mazine.
Reports on antipsychotics in
2003
The number of ADR reports totalled
936. Reports on antipsychotics to-
talled 63. One of the drugs reported
again was clozapine (26 reports),
whereas quetiapine and risperidone
were each the cause for reporting on
14 occasions. Five of the reports on
risperidone were associated with the
new, intramuscular route of admin-
istration. Olanzapine was reported
twice.
Antipsychotics and the elderly
The European Medical Evaluation
Authority (EMEA) and drug author-
ities round Europe have issued
warnings about the increased risk of
cerebrovascular disorders in patients
with dementia associated with the
use of olanzapine and risperidone.
The risk of death in this patient
group is also doubled with olanzap-
ine. Cerebrovascular disorders in de-
mentia patients associated with the
use of these drugs have not been re-
ported to the Finnish ADR register.
Over the last 10 years, the most
common of all suspected adverse re-
action involving over 65-year olds
(54 cases in all) was white blood
count changes (13), six of which
were suspected of having been
caused by clozapine. The second
most commonly reported adverse re-
actions related to malignant neuro-
leptic syndrome (11 cases), the sus-
pected cause of which was haloperi-
dol in four cases, periazine, olanzap-
ine and zuclopenthixol in two cases,
and risperidone in one case. Prolon-
gation of the QT interval was re-
ported in six cases, on two occa-
sions in association with sertindole
and risperidone, albeit in the one
case in combination with two other
antipsychotics.
Over the last 10 years, in the
group of 65-year-old patients, an an-
tipsychotic agent has been suspected
of having played a partial role in
causing a patient's death in six cas-
es, mostly owing to a malignant
neuroleptic syndrome. Two of the
fatal cases were associated with the
use of haloperidol, two with levome-
promazine and isolated cases with
the combined use of olanzapine and
risperidone, haloperidol and chlor-
prothixene.
Conclusion
About a half of the nearly one thou-
sand ADR reports on antipsychotics
concerned clozapine. The introduc-
tion of new drugs on to the market
is also reflected in the ADR reports
made: the new drugs have been re-
ported on frequently. They do not
appear to be without adverse effects.
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